Pharmaceutical Executive May 3, 2024
In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
PE: In Model N’s State of Revenue Report, many executives surveyed said they expect a significant impact from Medicare Part D drug price negotiations as part of the Inflation Reduction Act. How are companies preparing for this—and other changes aimed at more pricing transparency—in their go-to-market and commercial planning?
Mendolsohn: Obviously, for companies who have drugs on the “list” that are soon going to be subjected to maximum fair price under Medicare, there’s going to be an impact....
Today's Sponsors
Today's Sponsor